EGFR and lung adenocarcinoma: The advent of third-generation tyrosine kinase inhibitors (TKIs) has significantly improved the management of EGFR-mutated (EGFRm) lung adenocarcinoma (LUAD), establishing these inhibitors as the standard of care for first-line treatment [1,2,3].